Synonyms: BMS986224
Compound class:
Synthetic organic
Comment: BMS-986224 is an orally bioavailable small molecule apelin receptor agonist that was selected as a clinical lead with potential to treat heart failure [1-2]. Clinical development was discontinued at Phase 1.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Phase 1 clinical evaluations of BMS-986224 have been completed. Development appears to have been discontinued. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03634969 | An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants | Phase 1 Interventional | Bristol-Myers Squibb | ||
NCT03563950 | An Investigational Study to Evaluate the Effect of Rifampin on the Singe Dose of Experimental Medication BMS-986224 in Healthy Participants | Phase 1 Interventional | Bristol-Myers Squibb | ||
NCT03281122 | A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction | Phase 1 Interventional | Bristol-Myers Squibb |